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Objectives: Renal transplant patients receive calcineurin inhibitors to suppress the calcineurin-nuclear
factor of activated T cells (NFAT) pathway. The DNA binding activity of NFAT and its relationship to the
reactivation of BK virus (BKV) has not been evaluated in renal transplant patients.
Patients and Methods: The DNA binding activity of NFAT cytoplasmic 1 (NFATc1) was measured by
enzyme-linked immunosorbent assay in peripheral blood mononuclear cells from 26 renal transplant
patients and 26 healthy controls. At the same time, their urinary BKV viral load was measured by real-
time polymerase chain reaction.
Results: The activity of NFATc1 was lower in renal transplant patients without BKV viruria [BKV ()] than
in healthy controls, while it trended to be higher in renal transplant patients with BKV viruria [BKV (þ)]
than in BKV () patients. The tacrolimus blood levels did not differ between BKV (þ) and BKV () renal
transplant patients or correlate with NFATc1 activity.
Conclusion: NFATc1 DNA binding activity was lower in renal transplant patients without BKV viruria than
in those who were BKV (þ). However, there was no relationship between tacrolimus blood levels and
NFATc1 activity in renal transplant patients.
Copyright  2013, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC. All
rights reserved.1. Introduction
Calcineurin inhibitors, such as cyclosporine and tacrolimus, are
important immunosuppressive drugs in the prevention of renal
allograft rejection. Tacrolimus binds to the intracellular immuno-
philin FK506 binding protein (FKBP12), and this FKBP12-tacrolimus
complex inhibits the phosphatase activity of calcineurin [1]. In
immune cells, the major target molecule of calcineurin is the
transcription factor nuclear factor of activated T cells (NFAT). After
dephosphorylation by calcineurin, activated NFAT induces the
transcriptional activation of many important genes involved in the
immune response, including interleukin-2, interferon-g, and
granulocyte macrophage colony-stimulating factor. Tacrolimusunology, and Rheumatology,
g Road, Dalin, Chiayi, Taiwan.
).
ddhist Compassion Relief Tzu Chiinhibits calcineurin activity, thus suppressing the production of
these cytokines [2]. Although tacrolimus is highly effective in pre-
venting allograft rejection, it has some common adverse effects,
including nephrotoxicity, neurotoxicity, and diabetogenicity [3]. In
addition, the therapeutic range of tacrolimus is very narrow, and
the drug is known to have a large degree of inter- and intra-
individual pharmacokinetic variability [4]. Therapeutic drug
monitoring of trough blood concentrations is used clinically to
guide the adjustment of tacrolimus. However, allograft rejection
and tacrolimus-related adverse effects have occasionally developed
in patients whose blood levels were within the therapeutic range
[5]. This may be because the blood levels of tacrolimus do not al-
ways accurately reﬂect the effective level of tacrolimus-induced
immunosuppression. Recent studies have attempted to evaluate
the effective level of tacrolimus-induced immunosuppression by
measuring calcineurin phosphatase activity and monitoring NFAT-
regulated gene expression [6e8]. However, we could ﬁnd no
study that investigated the DNA binding activity of NFAT in renal
transplant patients.Foundation. Published by Elsevier Taiwan LLC. All rights reserved.
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general population, but signiﬁcant clinical manifestations are rare
except in patients with impaired immunity [9]. BKV primary
infection usually occurs in childhood without speciﬁc symptoms,
and the initial infection is followed by a nonreplicative state,
primarily in the urogenital tract. Asymptomatic reactivation and
low-level replication with viruria are observed in 5% of healthy
individuals. BKV reactivation in renal transplant patients may be
associated with nephropathy causing renal allograft failure [10,11].
The reactivation of BKV is related to the use of immunosuppres-
sants in renal transplant patients [12]. Therefore, in clinical prac-
tice, it is crucial to adjust the dose of an immunosuppressant to a
level that prevents acute rejection without leaving the patient
susceptible to new infections and reactivation of BKV in the urinary
tract.
In the present study, we ﬁrst compared the DNA binding activity
of NFAT cytoplasmic 1 (NFATc1) in peripheral blood mononuclear
cells (PBMCs) of renal transplant patients with and without BKV
viruria [BKV (þ) and BKV (), respectively] and healthy controls to
determine the level of tacrolimus-induced immunosuppression.
We then correlated BKV reactivation in renal transplant patients
and NFAT activity with the blood levels of tacrolimus.
2. Patients and methods
2.1. Patients
Twenty-six renal allograft recipients and 26 sex- and age-
matched healthy volunteers were recruited for the present study.
All participants gave informed consent and the study was approved
by the local Internal Review Board and Ethics Committee of
Buddhist Dalin Tzu Chi General Hospital, Chiayi, Taiwan (No.
B09602035). The personal and clinical data of the renal transplant
patients were recorded. Most of the transplant patients were pre-
scribed a protocol of a tacrolimus-based triple regimen that com-
bined tacrolimus with mycophenolic acid/mycophenolate mofetil
and prednisolone and did not include induction therapy. The blood
level of tacrolimus was adjusted to 10e15 mg/L during the
ﬁrst month post-transplantation, 8e12 mg/L the second month, and
6e8 mg/L thereafter. Acute rejectionwas noted in ﬁve (19.2%) of the
patients, and most of these cases were controlled by pulse therapy.
Tacrolimus was given every 12 hours and blood samples were
collected in the morning (6:00e7:00 AM) just prior to the morning
dose. Midstream urine specimens were collected in sterile con-
tainers without transport medium, immediately frozen, and stored
at 20C until analyzed. Tacrolimus blood levels were routinely
measured by microparticle enhancement immunoassay (Abbott
Diagnostics, North Chicago, IL, USA; detection limit <1.5 mg/L).
2.2. Measurement of the nuclear NFATc1 DNA binding activity of
PBMCs
Heparinized venous blood obtained from patients and healthy
volunteers was mixed with a 2% dextran solution (molecular
weight 464 kDa; Sigma-Aldrich, St. Louis, MO, USA) at a ratio of four
parts blood to one part dextran, and the resulting solution was
incubated at room temperature for 30 minutes. A leukocyte-
enriched supernatant was collected and layered over a Ficoll-
Hypaque density gradient solution (speciﬁc gravity 1.077;
Pharmacia Biotech, Uppsala, Sweden). After centrifugation of the
leukocyte-enriched supernatant at 250 g for 25 minutes, PBMCs
were aspirated from the interface. The PBMC suspension should
have contained 90% lymphocytes, 5e8%monocytes and 2e5% other
cells, which we conﬁrmed this with Giemsa staining. The PBMC cell
concentration was adjusted to 2  109/L in RPMI-1640supplemented with 10% heat-inactivated fetal bovine serum,
2mM L-glutamine, penicillin (100 U/mL) and streptomycin (100 mg/
mL; 10% fetal bovine serum-RPMI). Trypan blue dye exclusion was
performed to demonstrate that the viability of the PBMCs was
>95%. NE-PER nuclear and cytoplasmic extraction reagents (Pierce
Biotechnology, Rockford, IL, USA) were used to prepare nuclear
extracts from PBMCs according to the manufacturer’s protocol. The
DNA binding activity of NFATc1 in the nuclear extract was detected
with a sensitive multi-well colorimetric assay kit (Active Motif,
Carlsbad, CA, USA), and all samples were measured in the same
plate at the same time.
2.3. Quantiﬁcation of BKV viral load in urine by real-time
polymerase chain reaction
The tacrolimus blood levels in BKV (þ) and BKV () renal
transplant patients were compared. First, seven patients were
excluded who were taking cyclosporine (n ¼ 2) or rapamycin
(n ¼ 5) to prevent a potential confounding effect of these immu-
nosuppressants. Therefore tacrolimus blood levels were correlated
with BKV viruria or NFATc1 DNA binding activity in the PBMCs of 19
renal transplant patients in the following analysis.
DNA was extracted from midstream urine with a QIAamp DNA
kit (Qiagen, Hilden, Germany) according to the manufacturer’s
protocols. Then, BKV viral copy numbers were quantiﬁed by real-
time polymerase chain reaction (PCR) using an ABI 5700
sequence detection (Applied Biosystems, Foster City, California,
USA) system as previously described [13]. Primers for the BKV
capsid protein-1 gene were based on those used in a study by
Randhawa et al [14] and were: forward primer, 5ʹ-GCA GCT CCC
AAA AAG CCA AA-3ʹ; reverse primer, 5ʹ-CTG GGT TTA GGA AGC ATT
CTA-3ʹ. All patient samples were tested in duplicate, and the
number of BKV copies was calculated from a standard curve. In all
real-time PCR assays, the correlation coefﬁcient of the standard
curve was >0.980. Standard precautions were used to prevent
contamination during PCR ampliﬁcation. Both template-free con-
trol lanes and negative control samples (DNA extracted from
healthy human mononuclear cells) were included in each run.
2.4. Statistical analysis
All data are represented as mean  standard deviation. Statis-
tical signiﬁcance was assessed by the unpaired ManneWhitney
U test and Fisher’s exact test. Multiple linear or logistic regression
was applied to calculate the correlation coefﬁcient and signiﬁcance
between different parameters. A p-value <0.05 was considered
statistically signiﬁcant.
3. Results
3.1. BKV reactivation rate and viral load in urine from renal
transplant patients and healthy controls
Data from the renal transplant patients and healthy volunteers
are shown in Table 1. The prevalence of BKV viruria tended to be
higher in renal transplant patients (42.3%, 11/26) than in healthy
controls (15.4%, 4/26; p ¼ 0.064). The mean urine BKV viral load
[log(urine BKV DNA copy number/mL)] was signiﬁcantly higher in
transplant patients than controls (2.80  3.54 vs. 0.84  2.05,
p ¼ 0.0264). Besides the current use of immunosuppressants, all
other parameters measured were similar between the two groups.
The patients were then further divided into subgroups based on the
presence or absence of BKV viruria [BKV (þ) or BKV (), respec-
tively] to make comparisons between these subgroups that related
to tacrolimus.
Table 1
Personal and clinical data of renal transplant patients and healthy volunteers.
Transplant patients
(n ¼ 26)
Healthy controls
(n ¼ 26)
Age (y, mean  SD) 43.6  11.6 35.9  7.5
Sex (F:M) 12:14 16:10
Prevalence of BK viruria (%) 42.3% (11/26) * 15.4% (4/26)
Urine BKV viral load [log(urine
DNA copy numbers)]
2.80  3.54 ** 0.84  2.05
Acute rejection 19.2% (5/26) d
Immunosuppressants
Prednisolone 92.3% (24/26) d
Tacrolimus (FK-506) 73.1% (19/26) d
Cyclosporine 7.7% (2/26) d
Mycophenolate mofetil/
Mycophenolic acid
46.2% (12/26) d
Rapamycin 19.2% (5/26) d
Duration of treatment (months,
mean  SD)
45.0  22.5 d
*p ¼ 0.064 compared with controls; **p ¼ 0.0264 compared with controls.
SD ¼ standard deviation.
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() renal transplant patients and controls
Calcineurin inhibitors such as tacrolimus and cyclosporine are
the most common immunosuppressive drugs used in renal trans-
plant patients. NFATc1 is a transcription factor downstream of
calcineurin that is the key target of these immunosuppressive
drugs. The nuclear NFATc1 DNA binding activity was lower in
PBMCs from the BKV () group than PBMCs from healthy controls
(0.20  0.03 vs. 0.23  0.03, p ¼ 0.0292; Fig. 1). Conversely, a trend
of increased NFATc1 activity was found in PBMCs from BKV (þ)
patients compared with those from BKV () patients (0.24  0.08
vs. 0.20  0.03, p ¼ 0.0775).3.3. Correlation between clinical parameters and NFATc1 DNA
binding activity in PBMCs from renal transplant patients
Correlation of different clinical parameters with the NFATc1
DNA binding activity in PBMCs from renal transplant patients was
attempted by univariate andmultivariate linear regression analysis.
The NFATc1 DNA binding activity tended to be positively associatedFig. 1. Comparison of the nuclear DNA binding activity of nuclear factor of activated T
cells, cytoplasmic 1 (NFATc1) in peripheral blood mononuclear cells of renal transplant
patients with/without BK virus viruria [BKV (þ) and BKV (), respectively] and healthy
controls.with BKV viruria (p ¼ 0.078) and female gender (p ¼ 0.097). After
adjusting for age, the NFATc1 DNA binding activity still tended to be
positively associated with BKV viruria (p ¼ 0.086) and female
gender (p ¼ 0.086; Table 2).
3.4. Comparison of tacrolimus blood levels in BKV (þ) and BKV ()
renal transplant patients
From the results above, it was tentatively concluded that the
reactivation of BKV in the urinary tract was positively associated
with NFATc1 DNA binding activity and that this activity was sup-
pressed by calcineurin inhibitors. Thus, the next step was to mea-
sure tacrolimus blood levels in 19 renal transplant patients after
excluding those who were taking rapamycin or cyclosporine. Sur-
prisingly, tacrolimus blood levels did not differ between BKV (þ)
and BKV () renal transplant patients (Fig. 2A). Also, the percentage
of renal transplant patients with BKV viruria was quite similar
in those with lower (<5.5 mg/L) and higher tacrolimus drug levels
[ 5.5 mg/L; 44% (4/9) vs. 50% (5/10); p ¼ 1.000; Fig. 2B].
3.5. Correlation between tacrolimus blood levels and NFATc1 DNA
binding activity in PBMCs from renal transplant patients
There was no correlation between the level of tacrolimus in the
blood and NFATc1 DNA binding activity in PBMCs from19 renal
transplant patients after excluding those taking rapamycin or
cyclosporine (R2 ¼ 0.155, p ¼ 0.527; Fig. 3).
4. Discussion
Calcineurin inhibitors are the primary immunosuppressants
used as prophylaxis against allograft rejection in renal trans-
plantation. We focused on the calcineurin inhibitor tacrolimus in
the present study. Although monitoring tacrolimus blood levels
may be useful in preventing allograft rejection and infections, some
patients still experience acute rejection or become infected when
tacrolimus levels are within the therapeutic range [5]. In fact, the
blood concentration of tacrolimus does not accurately reﬂect the
level of tacrolimus-induced immunosuppression in clinical prac-
tice. This discrepancy may be due to genetic polymorphism in theTable 2
Univariate and multivariate liner regression models for assessing the correlations
among different clinical parameters and the NFATc1 DNA binding activity in pe-
ripheral blood mononuclear cells from renal transplant patients.
Univariate analysis
Fold change
(95% conﬁdence
interval)
Multivariate analysis
Fold change
(95% conﬁdence
interval)
Age (per 10 y) 0.008
(0.014e0.031)
0.0004
(0.017e0.025)
Sex (male/female) 0.040a
(0.089e0.008)
0.040b
(0.087e0.006)
Prevalence of BK viruria
(yes/no)
0.043c
(0.005e0.091)
0.042d
(0.006e0.090)
Tacrolimus (yes/no) 0.016
(0.041e0.073)
d
Cyclosporine (yes/no) 0.004
(0.100e0.091)
d
Mycophenolate mofetil/
mycophenolic acid (yes/no)
0.032
(0.017e0.081)
d
Rapamycin (yes/no) 0.016
(0.080e0.048)
d
ap ¼ 0.097; bp ¼ 0.086; cp ¼ 0.078; dp ¼ 0.086.
After analysis with multivariate linear regression model adjusted for age, the
presence of BK viruria (p ¼ 0.086) and female patient (p ¼ 0.086) were found ten-
dency to correlate with NFATc1 DNA binding activity in renal transplant patients.
Fig. 2. Comparison of tacrolimus blood levels and BK virus (BKV) viruria, (A) Tacroli-
mus blood levels in BKV (þ) and BKV () renal transplant patients. (B) The presence of
BKV viruria in renal transplant patients with lower (<5.5 mg/L) and higher tacrolimus
drug levels ( 5.5 mg/L). Renal transplant patients who were taking cyclosporine or
rapamycin were excluded.
W.-Y. Yin et al. / Tzu Chi Medical Journal 25 (2013) 112e116 115genes of the biotransformation enzyme (CYP3A5) and the trans-
porter protein ABCB1 [15]. Therefore several authors have
attempted to determine the level of tacrolimus-induced immuno-
suppression by measuring calcineurin phosphatase activity [16,17]
or the inhibition of NFAT-regulated gene expression [7] in PBMCs
from transplant patients. Although calcineurin activity in PBMCs
from transplant patients has been associated with acute rejection
[18,19], the measurement of calcineurin activity is complicated and
not clinically practical because it uses 32P [20,21]. The quantitative
analysis of NFAT-dependent gene expression before and after
treatment has been shown to be speciﬁc and is correlated with the
incidence of infection and malignancy [8,22]. In this study, NFATc1
DNA binding activity wasmeasured in PBMCs from renal transplant
patients by an enzyme-linked immunosorbent assay-basedmethod
[23]. This assay was easy to use, nonradioactive, highly reproduc-
ible, speciﬁc and sensitive for NFATc1, and suitable for high-
throughput screening, and is widely used in hematological and
immunological studies [24,25].
We found that the NFAT DNA binding activity tended to be lower
in PBMCs from renal transplant patients than those from healthy
controls (0.22  0.06 vs. 0.23  0.03; p ¼ 0.133). A possible reason
for this not reaching statistical signiﬁcance is that BKV reactivation
in renal transplant patients may elicit inﬂammation andFig. 3. Correlation of tacrolimus blood levels with nuclear factor of activated T cells,
cytoplasmic 1 (NFATc1) DNA binding activity in peripheral blood mononuclear cells
from renal transplant patients receiving tacrolimus. Renal transplant patients who
were taking cyclosporine or rapamycin were excluded.nephropathy, which in turn increase the NFAT activity in PBMCs.
This increased NFAT activity would counterbalance the tacrolimus-
induced suppression of NFAT. BKV viruria was found in nearly half
(42.3%) of the renal transplant patients in our study, which was
attributed to the use of various immunosuppressive drugs [26].
Thus, we divided the renal transplant patients into BKV (þ) and
BKV () subgroups for further analysis. We found that NFAT DNA
binding activity was higher in BKV (þ) than BKV () renal trans-
plant patients. We did not divide the healthy controls into sub-
groups according to their BKV reactivation status because BKV
reactivation was relatively infrequent (15.4%) and the NFAT activity
in healthy controls did not differ based on the BKV viruria status
(0.21  0.03 vs. 0.23  0.03; p ¼ 0.20). Furthermore, while BKV
reactivation is usually asymptomatic and transient in healthy in-
dividuals, our data concerning viral loads appear to indicate that
reactivation is more severe and persistent in renal transplant pa-
tients (Table 1).
We did not ﬁnd that the use of immunosuppressants could
lower the DNA binding activity of NFAT in our analysis (Table 2).
This may show that the DNA binding activities of NFAT in renal
transplant patients are affected by complex interactions between
various factors including the host immunity, rejection reaction,
different immunosuppressive drugs at different dosages, and in-
fections such as from the BK virus. Because of the small case
number, it was impossible to investigate these complex in-
teractions in our study. However it is quite interesting that we
found a statistical trend of elevated NFAT DNA binding activity
correlated with BKV viruria. It is conceivable that BKV viral infec-
tion may trigger the expression of inﬂammatory genes. However, it
has been shown that NFAT and the urine levels of cytokines
downstream of it, such as interleukin-2, interferon-g and gran-
ulocyte macrophage colony-stimulating factor, do not seem to be
increased in BKV viruria [27,28]. In contrast, Jordan et al [29] re-
ported that increased NFAT activity may promote BKV viral tran-
scription through binding directly to the BKV promoter. Recently, Li
et al [30] showed that overexpression of NFAT could promote BKV
replication and cyclosporine could inhibit BKV replication. Clini-
cally, our study showed that elevated NFAT activity also tended to
associate with BKV viruria. It is quite possible that increased NFAT
activity may be a potential risk factor for BKV reactivation in renal
transplant patients.
We note at least three drawbacks in the present study. The ﬁrst
is that we monitored the BKV viral load using urine, but not sera
samples. BKV viremia has a better predictive role than BKV viruria
in the development of BK nephropathy. Second, because this study
was a cross-sectional study and had a relatively small case popu-
lation, we could not show any association between NFAT activity
and the development of rejection ormalignancy, andwe only found
a statistical trend between NFAT activity and the presence of BKV
viruria. A longitudinal observational study enrolling more renal
transplant patients should be conducted to clarify this issue in the
future. The third drawback is that we did not elucidate the mo-
lecular basis showing how the elevated DNA binding activity of
NFAT leads to BKV reactivation in renal transplant patients. We
noted that one transplant patient had biopsy-proven BKV ne-
phropathy and his NFAT activity was 0.21, but it is difﬁcult to draw
any conclusions from a single case.
Our studies revealed no association between NFATc1 DNA
binding activity and the blood level of tacrolimus in transplant
patients. This may be because most of the patients were receiving a
low daily dosage of tacrolimus, which would correspond to the low
tacrolimus blood levels (5.4  2.1 mg/L) observed in the patients in
the study. Several studies have also shown great variability in the
expression of NFAT-regulated genes [31] and calcineurin phos-
phatase activity [32] in patients with low blood levels of tacrolimus
W.-Y. Yin et al. / Tzu Chi Medical Journal 25 (2013) 112e116116(<11.4 mg/L). In a clinical setting, it is important to evaluate the
immunosuppressive status of transplant patients with low tacro-
limus blood levels to avoid tacrolimus-related toxicity and allograft
rejection.
In conclusion, NFATc1 DNA binding activity was lower in renal
transplant patients without BKV viruria and did not correlate with
tacrolimus blood levels.
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